Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Harbour BioMed Joins $165M Cross Financing Round for Windward Bio to Advance Ultra-Long-Acting TSLP Immunotherapies

Fineline Cube May 8, 2026
Company Deals

Roche Acquires PathAI for $750M to Accelerate Digital Pathology and AI-Driven Diagnostic Transformation

Fineline Cube May 8, 2026
Company Deals

Bayer to Acquire Perfuse Therapeutics for Up to $2.45 Billion – Expands Ophthalmology Portfolio with Phase 2 Endothelin Receptor Antagonist

Fineline Cube May 7, 2026
Company Deals

Amoytop Biotech Launches RMB 1.53 Billion Convertible Bond Offering to Fuel R&D and Manufacturing Expansion

Fineline Cube May 7, 2026
Company Deals

Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates

Fineline Cube May 6, 2026
Policy / Regulatory

China’s National Drug Alliance Procurement Office Suspends Harbin Liqiang’s Loxoprofen Gel Patch Production and Imposes 18-Month VBP Ban

Fineline Cube May 8, 2026
Company Drug

Huadong Medicine’s Asthma Drug CXG87 Receives NMPA Filing Acceptance Following Successful Phase III Trial Against Symbicort

Fineline Cube May 8, 2026
Company Drug

Wuhan YZY Biopharma’s Bispecific Antibody M701 Receives NMPA Acceptance for Review in Malignant Ascites Treatment

Fineline Cube May 8, 2026
Company Deals

LaNova Medicines Secures Series B Funding to Advance Oncology Pipeline

Fineline Cube Jun 29, 2022

China-based LaNova Medicines has successfully closed a Series B financing round, raising an undisclosed sum...

Company Deals

GenFleet Collaborates with BioLineRx to Develop Motixafortide for Pancreatic Cancer in China

Fineline Cube Jun 29, 2022

China-based GenFleet Therapeutics has entered into a collaboration with Israel’s BioLineRx Ltd (NASDAQ: BLRX) to...

Company Deals

Henlius and Palleon Partner on HER2-Targeted Antibody-Sialidase Fusion Protein

Fineline Cube Jun 29, 2022

China-based Shanghai Henlius Biotech Inc. (HKG: 2696) announced a strategic partnership with US-based Palleon Pharmaceuticals...

Company R&D

Lundbeck Initiates TALISMAN Study on Multiple System Atrophy in China and EU

Fineline Cube Jun 28, 2022

Danish-based Lundbeck (OTCMKTS: HLUBF) has announced plans to initiate a global investigational study on multiple...

Company Deals

OCON Healthcare Partners with Bio Genuine for China Marketing Rights and Women’s Health Product Development

Fineline Cube Jun 28, 2022

Israel-based OCON Healthcare, a specialist in uterine drug delivery, has entered into a license agreement...

Company Deals

Expeclinlab Raises RMB 185 Million to Boost Clinical Mass Spectrometry Business

Fineline Cube Jun 28, 2022

Focused Photonics Inc’s (SHE: 300203) subsidiary Expeclinlab has secured RMB 185 million (USD 27.7 million)...

Company Deals

Beijing Luzhu Biotechnology Secures Series C Funding for Meningococcal Vaccine Development

Fineline Cube Jun 28, 2022

China-based Beijing Luzhu Biotechnology Co., Ltd has reportedly secured an undisclosed amount in a Series...

Company Drug

Eli Lilly’s Donanemab Receives Tacit Approval for Alzheimer’s Clinical Trial in China

Fineline Cube Jun 28, 2022

The Center for Drug Evaluation (CDE) website indicates that US major Eli Lilly’s (NYSE: LLY)...

Company Deals R&D

Hainan Lecheng Partners with Fosun Pharma on Innovative Medical Devices and Diagnostics

Fineline Cube Jun 28, 2022

The Hainan Boao Lecheng International Medical Tourism Pilot Zone Administration has formed a partnership with...

Company Drug

Recbio’s R520A mRNA COVID-19 Vaccine Receives Clinical Approval in the Philippines

Fineline Cube Jun 28, 2022

China-based Jiangsu Recbio Technology Co., Ltd has announced receiving clinical trial approval from the Food...

Company Drug

Pfizer’s Besponsa First Prescribed in China for Leukemia Treatment

Fineline Cube Jun 28, 2022

US major Pfizer (NYSE: PFE) has announced the first prescriptions for its leukemia therapy Besponsa...

Company

Kelun Pharmaceutical Receives USD 30 Million from MSD for Licensing Deal

Fineline Cube Jun 28, 2022

China-based Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) has announced receiving USD 30 million from...

Company Deals

ImmuneOnco Biopharmaceuticals Files for HKSE IPO with Comprehensive Tumor Immunotherapy Pipeline

Fineline Cube Jun 28, 2022

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd has submitted an initial public offering (IPO) filing to the...

Company Drug

Clover Biopharmaceuticals’ SCB-2019 COVID-19 Vaccine Shows Strong Immune Response in Third Shot Study

Fineline Cube Jun 28, 2022

China-based Clover Biopharmaceuticals Ltd (HKG: 2197) has published clinical data for its COVID-19 vaccine candidate...

Company Drug

Harbour BioMed Receives FDA Approval for HBM7008 Clinical Trials

Fineline Cube Jun 28, 2022

China-based Harbour BioMed (HKG: 2142) has announced receiving clinical trial approval from the US FDA...

Drug

Sinovac Biotech’s CoronaVac Receives Conditional Registration from South African Regulator

Fineline Cube Jun 28, 2022

China-based Sinovac Biotech Ltd (NASDAQ: SVA) has announced that the South African Health Products Regulatory...

Company Medical Device

Joysbio Develops Rapid Test for SARS-CoV-2 Omicron Subvariants BA.4 and BA.5

Fineline Cube Jun 28, 2022

China-based Joysbio (Tianjin) Biotechnology Co., Ltd. has developed a rapid test to diagnose the latest...

Company Deals

Antengene and BeiGene Collaborate on Selinexor and Tislelizumab Combination Trial for Lymphoma

Fineline Cube Jun 28, 2022

China-based Antengene Corporation Ltd (HKG: 6996) has announced a clinical trial collaboration with BeiGene Inc....

Policy / Regulatory

7th National VBP Round Venue Moved to Nanjing from Shanghai

Fineline Cube Jun 27, 2022

In a departure from previous practice, the 7th national volume-based procurement (VBP) round will not...

Company Drug

Sino Biopharmaceutical’s TQ-B3101 Accepted by NMPA for ROS1+ NSCLC Treatment

Fineline Cube Jun 27, 2022

China-based Sino Biopharmaceutical Ltd (HKG: 1177) has announced that the National Medical Products Administration (NMPA)...

Posts pagination

1 … 653 654 655 … 662

Recent updates

  • China’s National Drug Alliance Procurement Office Suspends Harbin Liqiang’s Loxoprofen Gel Patch Production and Imposes 18-Month VBP Ban
  • Harbour BioMed Joins $165M Cross Financing Round for Windward Bio to Advance Ultra-Long-Acting TSLP Immunotherapies
  • Huadong Medicine’s Asthma Drug CXG87 Receives NMPA Filing Acceptance Following Successful Phase III Trial Against Symbicort
  • Eli Lilly Reports 56% Revenue Surge in Q1 2026 Driven by Mounjaro and Zepbound Dominance, Raises Full-Year Guidance
  • Zai Lab Reports Q1 2026 Revenue Decline Amid Zejula Impact from Centralized Procurement, Offset by Xacduro Growth
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

China’s National Drug Alliance Procurement Office Suspends Harbin Liqiang’s Loxoprofen Gel Patch Production and Imposes 18-Month VBP Ban

Company Deals

Harbour BioMed Joins $165M Cross Financing Round for Windward Bio to Advance Ultra-Long-Acting TSLP Immunotherapies

Company Drug

Huadong Medicine’s Asthma Drug CXG87 Receives NMPA Filing Acceptance Following Successful Phase III Trial Against Symbicort

Company

Eli Lilly Reports 56% Revenue Surge in Q1 2026 Driven by Mounjaro and Zepbound Dominance, Raises Full-Year Guidance

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.